WA-KYMETA
10.3.2020 13:02:17 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com )—the communications company making mobile global—announced the commercial availability of its next generation flat panel electronically steered antenna platform, the Kymeta u8. The new u8 terminal paired with Kymeta’s hybrid satellite-cellular connectivity services transforms the purchase and consumption of mobile data with an all-inclusive hardware, connectivity and services monthly subscription starting at $999. The Kymeta u8 is the world’s only commercially available flat panel electronically steered antenna built specifically for mobility and designed for the needs of both military and commercial customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200310005297/en/
The Kymeta u8 antenna enables complete coverage of the Ku-band with highly reliable electronic beam steering and no moving parts. It is available as an antenna, as a terminal, or in flyaway configurations, and it can be paired with Kymeta’s new satellite and hybrid satellite-cellular connectivity solutions.
Powered by top satellite service and cellular operators throughout the world, Kymeta Connect makes buying hardware, connectivity, network services, and global support as simple and predictable as buying a mobile phone plan. A variety of satellite or satellite-cellular airtime packages are available and provided in partnership with Intelsat and Cubic Telecom, among others. Customers will now have access to easily deployable and dependable mobile connectivity in places where reliable and affordable connectivity has not been available. Kymeta is also working with LEO satellite operators on technology and service collaborations as described in press announcements released during Satellite 2020.
“With our new u8 terminal paired with Kymeta Broadband connectivity and support, we are making mobile global with a fully managed, optimized, and easy to use blended service,” said Walter Berger, President and Chief Operating Officer, Kymeta. “It is a complete solution with an elegant simplicity that will be very attractive to companies who need predictable OPEX pricing for their regional mobile connectivity services. We believe this is an industry tipping point for unlocking new access to the internet in all parts of the world.”
“We look forward to expanding our successful partnership with Kymeta as they add Intelsat’s FlexMove managed service to their communications-on-the-move (COTM) connectivity solutions offerings. Working together, Kymeta and Intelsat are helping people stay connected wherever they need to be, no matter how remote or challenging the location,” said Samer Halawi, Chief Commercial Officer, Intelsat.
Kymeta’s mobile connectivity services will be available in the US, Europe, the Middle East, Asia Pacific, sub-Saharan Africa, and Oceania with services extending to future geographies in the coming months. Initial deployments will include the military, first responders, buses, vehicle fleets, small maritime vessels, ferries, trucks and trains.
Show attendees can sign up for a meeting or live driving demonstration of the Kymeta u8 by emailing marketing@Kymetacorp.com . Additionally, the Kymeta u8 video is live and available to watch at www.kymetacorp.com .
About Kymeta
Kymeta is unlocking the potential of satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for mobile connectivity. The company’s flat-panel satellite antenna, the first of its kind, and Kymeta™ Connect connectivity services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom